Cite

HARVARD Citation

    Fogelman, D. et al. (n.d.). Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer medicine. pp. 5382-5393. [Online]. 
  
Back to record